Libbs Farmacêutica LTDA
Brazilian pharmaceutical company that develops, manufactures and commercializes small-molecule and biological medicines. Operates an industrial biomanufacturing platform for biosimilars and monoclonal antibodies, offers CDMO and technology-transfer services, runs internal and open-innovation programs, and provides patient and healthcare-professional education and digital resources.
Industries
Nr. of Employees
Very Large (1000+)
Products
Biosimilar monoclonal antibodies
Development and industrial production of biosimilar monoclonal antibodies for oncology and autoimmune indications.
Cardiometabolic small-molecule portfolio
Range of small-molecule medicines for cardiovascular and metabolic conditions.
Dermatology and skin-care product lines
Topical and skin-care products formulated for photoprotection, melasma, dry and sensitive skin and atopic dermatitis; packaging updates include QR-code content for patients.
Biosimilar monoclonal antibodies
Development and industrial production of biosimilar monoclonal antibodies for oncology and autoimmune indications.
Cardiometabolic small-molecule portfolio
Range of small-molecule medicines for cardiovascular and metabolic conditions.
Dermatology and skin-care product lines
Topical and skin-care products formulated for photoprotection, melasma, dry and sensitive skin and atopic dermatitis; packaging updates include QR-code content for patients.
Services
Development and commercial manufacturing services for biological medicines including process development, scale-up, and final packaging.
Services to transfer manufacturing technology and optimize yields and process consistency for biological products.
Program to support investigator-initiated studies and strengthen local scientific research.
Program to connect with startups, scale-ups and small companies for collaborative innovation and access to company facilities.
Development and commercial manufacturing services for biological medicines including process development, scale-up, and final packaging.
Services to transfer manufacturing technology and optimize yields and process consistency for biological products.
Program to support investigator-initiated studies and strengthen local scientific research.
Program to connect with startups, scale-ups and small companies for collaborative innovation and access to company facilities.
Expertise Areas
- Biosimilar development
- Monoclonal antibody manufacturing
- Bioprocess development and scale-up
- CDMO services for biologics
Key Technologies
- Single-use bioprocessing systems
- Monoclonal antibody production workflows
- Biosimilar comparability and characterization methods
- Cell line development and cell banking
News & Updates
Announcement of the inauguration of a pilot biomanufacturing plant and a factory for high-potency medicines, reported as occurring 11 December 2024.
Launch of a supplier/partner relationship program in June 2025 aimed at recognizing and valuing suppliers.
Update of product packaging to include additional information and QR-code content, aligned with recent regulatory packaging requirements.
Notification of regional stock shortages for a laxative product due to a supply-chain incident, with actions underway to normalise supply; customers advised to consult their clinicians.
Operation of an industrial-scale facility for monoclonal antibody production.
Company classified as an excellent place to work for multiple consecutive years.
Announcement of the inauguration of a pilot biomanufacturing plant and a factory for high-potency medicines, reported as occurring 11 December 2024.
Launch of a supplier/partner relationship program in June 2025 aimed at recognizing and valuing suppliers.
Update of product packaging to include additional information and QR-code content, aligned with recent regulatory packaging requirements.
Notification of regional stock shortages for a laxative product due to a supply-chain incident, with actions underway to normalise supply; customers advised to consult their clinicians.
Operation of an industrial-scale facility for monoclonal antibody production.
Company classified as an excellent place to work for multiple consecutive years.